Kerry, PFI enter licensing partnership for development of joint health formulas
Kerry entered into a strategic licensing partnership with Pharma Foods International Co. Ltd. (PFI) in which Kerry has access to the joint health technology developed by PFI.
Photo © iStockphoto.com/monkeybusinessimages
Kerry (Dublin, Ireland) entered into a strategic licensing partnership with Pharma Foods International Co. Ltd. (PFI; Kyoto, Japan) in which Kerry has access to the joint health technology developed by PFI. The ingredient promotes the natural production of hyaluronic acid, keeping joints lubricated and mobile and ultimately helping to reduce discomfort and stiffness in knee joints and providing benefit to people with osteoarthritis.
“Our proprietary consumer research has revealed that consumers want healthy lifestyle products that also have a positive impact on bone and joint health,” said John Quilter, vice president and general manager for Kerry’s ProActive Health business, in a press release. “Today’s consumers are more informed about the ingredients in their functional products – with 56% reporting that they regularly research ingredients that can help improve health. We are delighted to partner with PFI, a leader in functional ingredient innovation, on this new joint health technology that will complement our portfolio of science-backed branded ingredients, including GanedenBC30 probiotic, Wellmune yeast beta glucan, and our most recent addition, Bio-K Plus probiotics.”
Because the ingredient is water-soluble, it has no impact on taste. It has already been formulated into several products in the Japanese market, and Kerry will be developing a brand positioning for the technology, supporting application and development and supplying the ingredient to customers across the world.
“We are very pleased and excited to be working with Kerry,” said CEO of PFI, Dr. Mujo Kim, in a press release. “PFI has been researching and developing original unique materials for the global market and now that we have established a cooperative relationship with Kerry, we will be able to accelerate our global expansion. We expect strong synergies between PFI’s research capabilities and Kerry’s global commercial network.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
